These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 21847900)

  • 1. Hidden truth: The perils and protection of off-label drug and medical device promotion.
    Conko G
    Health Matrix Clevel; 2011; 21(1):149-87. PubMed ID: 21847900
    [No Abstract]   [Full Text] [Related]  

  • 2. Off-label prescription advertising, the FDA and the First Amendment: a study in the values of commercial speech protection.
    Klasmeier C; Redish MH
    Am J Law Med; 2011; 37(2-3):315-57. PubMed ID: 21847884
    [No Abstract]   [Full Text] [Related]  

  • 3. Off-label drug use and promotion: balancing public health goals and commercial speech.
    Kesselheim AS
    Am J Law Med; 2011; 37(2-3):225-57. PubMed ID: 21847880
    [No Abstract]   [Full Text] [Related]  

  • 4. The future of off-label marketing regulations in the post-Sorrell era.
    Iraggi J
    Seton Hall Law Rev; 2013; 43(3):1137-63. PubMed ID: 23802338
    [No Abstract]   [Full Text] [Related]  

  • 5. Manufacturers' promotion of off-label drug use: implications for drug safety.
    Zieve A; Carome MA
    Expert Opin Drug Saf; 2016 Sep; 15(9):1149-51. PubMed ID: 27145440
    [No Abstract]   [Full Text] [Related]  

  • 6. Off-label promotion: government theories of prosecution and facts that drive them.
    Burroughs AD; Levy MC; Schwab GG; Paik Y
    Food Drug Law J; 2010; 65(3):555-88. PubMed ID: 24479242
    [No Abstract]   [Full Text] [Related]  

  • 7. The commercial speech doctrine in health regulation: the clash between the public interest in a robust First Amendment and the public interest in effective protection from harm.
    Orentlicher D
    Am J Law Med; 2011; 37(2-3):299-314. PubMed ID: 21847883
    [No Abstract]   [Full Text] [Related]  

  • 8. An unhealthy disregard.
    Nat Med; 2010 Jun; 16(6):609. PubMed ID: 20526289
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmaceuticals and medical devices: FDA oversight. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2010 Jan; ():1-31. PubMed ID: 20217914
    [No Abstract]   [Full Text] [Related]  

  • 10. Off-Label Marketing's Audiences: The 21
    Halabi SF
    Am J Law Med; 2018 May; 44(2-3):181-196. PubMed ID: 30106659
    [No Abstract]   [Full Text] [Related]  

  • 11. Free speech rights outweigh restrictions on promoting drugs off label, court rules.
    Roehr B
    BMJ; 2012 Dec; 345():e8324. PubMed ID: 23220261
    [No Abstract]   [Full Text] [Related]  

  • 12. Off-label marketing and the First Amendment.
    Boumil MM
    N Engl J Med; 2013 Jan; 368(2):103-5. PubMed ID: 23234470
    [No Abstract]   [Full Text] [Related]  

  • 13. FDA regulation of off-label drug promotion under attack.
    Kesselheim AS; Mello MM; Avorn J
    JAMA; 2013 Feb; 309(5):445-6. PubMed ID: 23385267
    [No Abstract]   [Full Text] [Related]  

  • 14. Targeting drug companies' bottom line.
    Prescrire Int; 2011 Jan; 20(112):25. PubMed ID: 21462792
    [No Abstract]   [Full Text] [Related]  

  • 15. The ban on "off-label" pharmaceutical promotion: constitutionally permissible prophylaxis against false or misleading commercial speech?
    Greenwood K
    Am J Law Med; 2011; 37(2-3):278-98. PubMed ID: 21847882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating promotional claims as false or misleading.
    Brushwood DB; Knox CA; Liu W; Jenkins KA
    Am J Health Syst Pharm; 2013 Nov; 70(21):1941-4. PubMed ID: 24128969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health related claims, the market for information, and the first amendment.
    Beales JH
    Health Matrix Clevel; 2011; 21(1):7-30. PubMed ID: 21847896
    [No Abstract]   [Full Text] [Related]  

  • 18. GlaxoSmithKline is fined record $3bn in US.
    Roehr B
    BMJ; 2012 Jul; 345():e4568. PubMed ID: 22761252
    [No Abstract]   [Full Text] [Related]  

  • 19. After Amarin v FDA: What Will the Future Hold for Off-label Promotion Regulation?
    Mackey TK; Liang BA
    Mayo Clin Proc; 2016 Jun; 91(6):701-6. PubMed ID: 27084416
    [No Abstract]   [Full Text] [Related]  

  • 20. To ban or not to ban--that is the question: the constitutionality of a moratorium on consumer drug advertising.
    Schwartz MI
    Food Drug Law J; 2008; 63(1):1-33. PubMed ID: 18561453
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.